Leaps by Bayer

Portfolio Co Investors 2026 for Leaps by Bayer: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Leaps by Bayer accounts for 30 tracked companies with verified cap-table data, 30 of which disclose round sizes totalling $4.8B. The median disclosed raise is $123M, and the largest is EGenesis at $481M, ahead of BridgeHealth ($450M) and Huma ($360M).

The names that recur most often on these co-invested cap tables are Leaps by Bayer (30 companies), Polaris Partners (7 companies), Alexandria Venture Investments (7 companies), ARCH Venture Partners (4 companies), General Catalyst (3 companies), 7wireVentures (3 companies). By latest disclosed round, the market skews Series B (12), Series A (8), Series D (4), Series C (2).

Best funded Leaps by Bayer companies

  1. EGenesis — $481M (latest: Series D)
  2. BridgeHealth — $450M (latest: Series D)
  3. Huma — $360M (latest: Series D)
  4. Pyxis Oncology — $326M (latest: IPO)
  5. Metagenomi — $300M (latest: Series B)
  6. Dewpoint Therapeutics — $287M (latest: Series C)
  7. SonoThera — $215M (latest: Series B)
  8. Nuvig Therapeutics — $208M (latest: Series B)
  9. Soufflé Therapeutics — $200M (latest: Series A)
  10. Sudo Biosciences — $188M (latest: Series B)
  11. Affini-T Therapeutics — $175M (latest: Seed)
  12. Capstan Therapeutics — $165M (latest: Series A)
  13. Century Therapeutics — $160M (latest: Series C)
  14. Sound Agriculture — $150M (latest: Growth)
  15. NextPoint Therapeutics — $123M (latest: Series B)

Leaps by Bayer — related firms and companies (56)

Leaps by Bayer alternatives · All research reports